Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

92.57 +1.48 (+1.62%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
52 53 Next >
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market. 
Via InvestorPlace
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Completes Acquisition of MiroBio
From Gilead Sciences, Inc.
Via Business Wire
WHO Recommends Gilead's COVID-19 Therapy For Severe Disease
Via Benzinga
Why Is Gilead Sciences (GILD) Stock Up Today?
Gilead Sciences has a low valuation, but no growth. Perhaps settling a patent lawsuit will help give GILD stock the boost it needs. 
Via InvestorPlace
Gilead's Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings
Via Benzinga
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.63% on an annualized basis producing an average annual return of 7.98%. Currently, Gilead Sciences has a market... 
Via Benzinga
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
Via Benzinga
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
As cases of the monkeypox virus continue to grow, the race is on for a way to fight this once-rare disease.  Since the first reports of monkeypox infection in the United States started popping up in... 
Via Benzinga
7 Penny Stocks That Actually Have a Buy Rating
Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now. 
Via InvestorPlace
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Kite Pharma's CAR T-Cell Therapy Wins European Approval In Refractory Leukemia Setting
Via Benzinga
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
From Gilead Sciences, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
Via Benzinga
Delayed Generic Entry Is Positive For This Large Pharma's HIV Franchise Sales, Analyst Says
Gilead Sciences Inc (NASDAQ: GILD) disclosed agreements with generic manufacturers that delay the U.S. launch of generic TAF products from 2025 to 2031/2032.  
Via Benzinga
Taking Charge of Your Care This Blood Cancer Awareness Month
(BPT) - Being empowered often comes from being informed. And when it comes to diseases like blood cancer, having or not having information can make a significant difference in outcomes. 
Via Brandpoint
Topics Death
Exposures Death
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
Via Benzinga
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."  The... 
Via Benzinga
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
From Gilead Sciences, Inc.
Via Business Wire
Why HIV Testing Should Be an Important and Normal Part of Your Self-Care Routine
(BPT) - The COVID-19 pandemic introduced unprecedented challenges and altered ways of living across the globe. Now, more than two years later, the effects are still felt widely. Many non-emergent... 
Via Brandpoint
Exposures COVID-19
Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?
Making its debut on 05/08/2007, smart beta exchange traded fund First Trust Large Cap Core AlphaDEX ETF (ETF:FEX) provides investors broad exposure to the Style Box - Large Cap Blend category of the... 
Via Benzinga
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
From Gilead Sciences, Inc.
Via Business Wire
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
From Gilead Sciences, Inc.
Via Business Wire
Gilead's Breast Cancer Drug Improves Progression-Free Survival in HR+/HER2- Metastatic Breast Cancer
Via Benzinga
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
From Gilead Sciences, Inc.
Via Business Wire
Everest Medicines Descends To New Depths On String Of Bad News
Key Takeaways: The CEO of Everest Medicines resigned two days after the company announced its loss grew sharply in the first half of the year The company also lost an important potential new revenue... 
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.